Intuitive Surgical
Q1 2022 Earnings Call
Apr 21, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by and welcome to the Intuitive Q1 2022 earnings release. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator instructions] And as a reminder, your conference is being recorded.
I would now like to turn the conference over to your host, Brian King, Head of Investor Relations. Please go ahead.
Brian King -- Treasurer and Head of Investor Relations
Good afternoon, and welcome to Intuitive's first-quarter earnings conference call. With me today, we have Gary Guthart, our CEO; and Jamie Samath, CFO. Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties.
These risks and uncertainties are described in detail in our Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 3, 2022. Our SEC filings can be found through our website or at the SEC's website. Investors are cautioned not to place undue reliance on such forward-looking statements. Please note that this conference call will be available for audio replay on our website at intuitive.com on the Events section under our Investor Relations page.
Today's press release and supplementary financial data tables have been posted to our website. Today's format will consist of providing you with highlights of our first-quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Jamie will provide a review of our financial results, then I will discuss procedure and clinical highlights and provide our updated financial outlook for 2022.
And finally, we will host a question-and-answer session. With that, I will turn it over to Gary.
Gary Guthart -- Chief Executive Officer
Thank you for joining us today. In the first quarter, procedure demand for our products was healthy, recovering where COVID receded. Drivers of procedure performance included general surgery in the U.S. and non-urology procedures outside of the U.S., which are our areas of focus.
Regardless of the health of procedure demand, we are challenged by environmental stresses, including regional waves of COVID, staffing pressure at hospitals, component and raw material availability, and logistic delays. While it's difficult to forecast how long these headwinds will persist, our teams are working hard to meet the challenge. In the quarter, da Vinci procedures grew 19% compared to the first quarter of 2021. The use of da Vinci in general surgery in the United States grew nicely, led by bariatric procedures, cholecystectomy, hernia repair, and rectal surgery.